# ALF-STONE: Alfuzosin in Uretheric Stones

> **NCT00454402** · PHASE3 · TERMINATED · sponsor: **Sanofi** · enrollment: 220 (estimated)

## Conditions studied

- Prostatic Hyperplasia

## Interventions

- **DRUG:** Alfuzosin

## Key facts

- **NCT ID:** NCT00454402
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-08
- **Primary completion:** —
- **Final completion:** 2007-07
- **Target enrollment:** 220 (ESTIMATED)
- **Why stopped:** Discontinued due to incomplete recruitment
- **Last updated:** 2007-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00454402

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00454402, "ALF-STONE: Alfuzosin in Uretheric Stones". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00454402. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*